CLEVELAND, Dec. 11, 2008 (GLOBE NEWSWIRE) -- Athersys, Inc. (NasdaqCM:ATHX - News) announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of administration of its ``off-the-shelf’’ adult stem cell product, MultiStem(r), in the treatment of ischemic stroke.
